Hypercholesterolemia - non-pharmacological treatment, monotherapy or combination therapy. Review of the literature
DOI:
https://doi.org/10.12775/QS.2024.19.54155Keywords
hypercholesterolemia, LDL-C, Statin, Ezetemibe, PCSK-9Abstract
Introduction:
As the number of scientific studies on lipid metabolism disorders increases, awareness among the medical community and the general population about the impact of hypercholesterolemia on the risk of cardiovascular diseases is growing. Elevated cholesterol levels in the blood are a major factor in the development of atherosclerosis, thereby increasing the likelihood of sudden cardiovascular events such as heart attacks or strokes. Maintaining normal cholesterol levels in the blood requires effective collaboration between the doctor and the patient, combining optimal pharmacotherapy with effective non-pharmacological methods based on the introduction of a balanced diet and moderate, regular physical activity. Current guidelines, based on numerous scientific studies, provide a clear framework for lipid-lowering treatment, with statins being an integral part. In cases where monotherapy is ineffective, ezetimibe and monoclonal antibodies, among others, can be used. In our work, we will discuss the possibilities of both non-pharmacological therapy and pharmacotherapy.
Aim of the study:
The aim of this study is to review current knowledge on non-pharmacological and pharmacological therapy in hypercholesterolemia.
Material and method:
This article presents the current state of knowledge about non-pharmacological and pharmacological therapy in hypercholesterolemia. Publications reviewed using the PubMed platform contain recent report in field of lipid metabolism disorders. The search included the keywords: ‚Hypercholesterolemia’, ‚LDL-C’, ‚Statin’, ,Ezetimibe’, ,PCSK9 inhibitors’.
References
red.Piotr Gajewski, Interna Szczeklika 2023, Kraków, Polska: Medycyna Praktyczna, 2023.
Smart N.A., Marshall B.J., Daley M. i wsp. Low-fat diets for acquired hypercholesterolaemia (Review). The Cochrane Library 2011; 2.
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37: 2999–3058.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Boren J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgozoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Lowdensity lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38: 2459–2472.
Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe – epidemiological update. 2015. Eur Heart J. 2015; 36: 2696–2705.
Cooney MT, Dudina A, Whincup P, Capewell S, Menotti A, Jousilahti P, Njolstad I, Oganov R, Thomsen T, Tverdal A, Wedel H, Wilhelmsen L, Graham I; SCORE Investigators. Re‑evaluating the Rose approach: comparative benefits of the population and high‑risk preventive strategies. Eur J Cardiovasc Prev Rehabil. 2009; 16: 541–549.
Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta‑analysis of 60 controlled trials. Am J Clin Nutr. 2003; 77: 1146–1155.
Estruch R, Ros E, Salas‑Salvadó J, Covas MI, Corella D, Arós F, Gómez‑Gracia E, Ruiz‑Gutiérrez V, Fiol M, Lapetra J, Lamuela‑Raventos RM, Serra‑Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez‑González MA. Retraction and republication: primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2018; 378: 2441–2442.
Micha R, Khatibzadeh S, Shi P, Fahimi S, Lim S, Andrews KG, Engell RE, Powles J, Ezzati M, Mozaffarian D; Global Burden of Diseases Nutrition and Chronic Diseases Expert Group NutriCoDE. Global, regional, and national consumption levels of dietary fats and oils in. 1990 and. 2010: a systematic analysis including 266 country‑specific nutrition surveys. BMJ. 2014; 348: g2272.
Schwingshackl L, Bogensberger B, Bencic A, Knuppel S, Boeing H, Hoffmann G. Effects of oils and solid fats on blood lipids: a systematic review and network meta‑analysis. J Lipid Res. 2018; 59: 1771–1782.
Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, James WP, Finer N. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta‑analysis. Obes Rev. 2016; 17: 1001–1011.
Look Ahead Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak‑Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi‑Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013; 369: 145–154.
Batsis JA, Gill LE, Masutani RK, Adachi‑Mejia AM, Blunt HB, Bagley PJ, Lopez‑Jimenez F, Bartels SJ. Weight loss interventions in older adults with obesity: a systematic review of randomized controlled trials since. 2005. J Am Geriatr Soc. 2017; 65: 257–268.
Huffman KM, Hawk VH, Henes ST, Ocampo CI, Orenduff MC, Slentz CA, Johnson JL, Houmard JA, Samsa GP, Kraus WE, Bales CW. Exercise effects on lipids in persons with varying dietary patterns‑does diet matter if they exercise? Responses in studies of a targeted risk reduction intervention through defined exercise I. Am Heart J. 2012; 164: 117–124.
Maeda K, Noguchi y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a metaanalysis. Prev Med. 2003; 37: 283–290
Baratta F, Angelico F, Del Ben M. Challenges in Improving Adherence to Diet and Drug Treatment in Hypercholesterolemia Patients. Int J Environ Res Public Health. 2023;20(10):5878. Published 2023 May 19. doi:10.3390/ijerph20105878
Musa‑Veloso K, Poon TH, Elliot JA, Chung C. A comparison of the LDL‑cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a metaanalysis of randomized, placebo‑controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2011; 85: 9–28.
Gylling H, Plat J, Turley S, Ginsberg HN, Ellegård L, Jessup W, Jones PJ, Lütjohann D, Maerz W, Masana L, Silbernagel G, Staels B, Borén J, Catapano AL, DeBacker G, Deanfield J, Descamps OS, Kovanen PT, Riccardi G, Tokgözoglu L, Chapman MJ; European Atherosclerosis Society Consensus Panel on Phytosterols. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014; 232: 346–360
Poli A, Barbagallo CM, Cicero AFG, Corsini A, Manzato E, Trimarco B, Bernini F, Visioli F, Bianchi A, Canzone G, Crescini C, de Kreutzenberg S, Ferrara N, Gambacciani M, Ghiselli A, Lubrano C, Marelli G, Marrocco W, Montemurro V, Parretti D, Pedretti R, Perticone F, Stella R, Marangoni F. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. Pharmacol Res. 2018; 134: 51–60
De Backer GG. Food supplements with red yeast rice: more regulations are needed. Eur J Prev Cardiol. 2017; 24: 1429–1430
Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM; Chinese Coronary Secondary Prevention Study Group, Li S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008; 101: 1689–1693.
Li Y, Jiang L, Jia Z, Xin W, Yang S, Yang Q, Wang L. A metaanalysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One. 2014; 9: e98611.
Hartley L, May MD, Loveman E, Colquitt JL, Rees K. Dietary fibre for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2016; 1: CD011472.
Pirro M, Vetrani C, Bianchi C, Mannarino MR, Bernini F, Rivellese AA. Joint position statement on „Nutraceuticals for the treatment of hypercholesterolemia” of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2017; 27: 2–17.
Dewell A, Hollenbeck PL, Hollenbeck CB. Clinical review: a critical evalation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. J Clin Endocrinol Metab. 2006; 91: 772–780.
Mozaffarian D, Lemaitre RN, King IB, Song X, Huang H, Sacks FM, Rimm EB, Wang M, Siscovick DS. Plasma phospholipid long‑chain omega‑3 fatty acids and total and cause‑specific mortality in older adults: a cohort study. Ann Intern Med. 2013; 158: 515–525.
Sacks FM, Lichtenstein AH, Wu JH Y, Appel LJ, Creager MA, Kris‑Etherton PM, Miller M, Rimm EB, Rudel LL, Robinson JG, Stone NJ, Van Horn LV; American Heart Association. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2017; 136: e1‑e23.
Rivellese AA, Maffettone A, Vessby B, Uusitupa M, Hermansen K, Berglund L, Louheranta A, Meyer BJ, Riccardi G. Effects of dietary saturated, monounsaturated and n‑3 fatty acids on fasting lipoproteins, LDL size and postprandial lipid metabolism in healthy subjects. Atherosclerosis. 2003; 167: 149–158.
Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low‑density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012; 6: 5–18.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE‑IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019; 380: 11–22.
E. Mutschler, G. Geisslinger, H.K. Kroemer, S. Menzel, P. Ruth Farmakologia i Toksykologia, Wrocław, Polska MEDPHARM 2016
Lis A, Lis P, Łowicka W, Grabarczyk M, Wita M, Żarczyński P, Żarczyńska M, Haberka M. Lipid-Lowering Treatment and the Lipid Goals Attainment in Patients with a Very High Cardiovascular Risk. Journal of Cardiovascular Development and Disease. 2023; 10(8):329. https://doi.org/10.3390/jcdd10080329
Banach, M.; Burchardt, P.; Chlebus, K.; Dobrowolski, P.; Dudek, D.; Dyrbuś, K.; Gąsior, M.; Jankowski, P.; Jóźwiak, J.; Kłosiewicz-Latoszek, L.; et al. Wytyczne PTL/KLRwP/PTK/PTDL/PTD/PTNT diagnostyki i leczenia zaburzeń lipidowych w Polsce 2021. Lekarz POZ Supl. 2021. Available online: https://ptlipid.pl/wp-content/uploads/2021/09/Wytyczne-PTL2021_Wersja-Pre-Print.pdf (accessed on 25 June 2024).
Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73(24):3210–3227. doi:10.1016/j.jacc.2018.11.004 5.
Cannon CP, Blazing MA, Giugliano RP, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372(25):2387–2397. doi:10.1056/NEJMoa1410489 6.
Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376(18):1713–1722. doi:10.1056/NEJMoa1615664 7.
Schwartz GG, Steg PG, Szarek M, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379(22):2097–2107. doi:10.1056/NEJMoa1801174
Kausik K. Ray, Bart Molemans,W. Marieke Schoonen et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DAVINCI study. Eur J Prev Cardiol 2020; doi:10.1093/eurjpc/zwaa047.
Vrablik M, Seifert B, Parkhomenko A, Banach M, Jozwiak JJ, Kiss RG, Gaita D, Raslova K, Zachlederova M, Ray KK. Are risk-based LDL-C goals achieved in primary and secondary care in Central and Eastern Europe? Comparison with other Europe regions from the DA VINCI observational study. Atherosclerosis 2021; (in press).
De Backer G, Jankowski P, Kotseva K, et al.; EUROASPIRE V collaborators. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESCEORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019 Jun;285:135-146.
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open‐Label Study of Long‐Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1500–1509.
Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012; 8: 415–427.
Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34: 154–156.
Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014; 54: 273–293.
Nozue T. Lipid lowering therapy and circulating PCSK9 concentration. J Atheroscler Thromb. 2017; 24: 895–907
Toth, PP; Banach, M. Statyny: dawniej i dziś. Methodist DeBakey Cardiovasc. J. 2019 , 15 , 23–31
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Weronika Łowicka, Magdalena Graca, Anna Szeliga, Agata Szostak, Karolina Korta, Karolina Oluszczak, Kinga Szopińska, Liliana Dyląg, Maria Janina Śmigielska-Mikołajczyk, Konrad Wawszkowicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 57
Number of citations: 0
